Citação norma APA

Bertino, E. M., Gentzler, R. D., Clifford, S., Kolesar, J., Muzikansky, A., Haura, E. B., . . . Oxnard, G. R. (2020). Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). Clin Cancer Res.

Citação norma Chicago

Bertino, Erin M., et al. "Phase IB Study of Osimertinib in Combination With Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)." Clin Cancer Res 2020.

Citação norma MLA

Bertino, Erin M., et al. "Phase IB Study of Osimertinib in Combination With Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)." Clin Cancer Res 2020.

Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.